304 related articles for article (PubMed ID: 19615492)
1. Heart rate in coronary syndromes and heart failure.
Orso F; Baldasseroni S; Maggioni AP
Prog Cardiovasc Dis; 2009; 52(1):38-45. PubMed ID: 19615492
[TBL] [Abstract][Full Text] [Related]
2. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
Bruguera Cortada J; Varela A
Am J Cardiovasc Drugs; 2009; 9 Suppl 1():9-12. PubMed ID: 20000882
[TBL] [Abstract][Full Text] [Related]
3. Heart rate as a treatable cardiovascular risk factor.
Tardif JC
Br Med Bull; 2009; 90():71-84. PubMed ID: 19474056
[TBL] [Abstract][Full Text] [Related]
4. Rate control with ivabradine: angina pectoris and beyond.
Parakh N; Bhargava B
Am J Cardiovasc Drugs; 2011; 11(1):1-12. PubMed ID: 21090826
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
[TBL] [Abstract][Full Text] [Related]
6. Ivabradine: beyond heart rate control.
Riccioni G; Vitulano N; D'Orazio N
Adv Ther; 2009 Jan; 26(1):12-24. PubMed ID: 19165437
[TBL] [Abstract][Full Text] [Related]
7. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.
Fox K; Komajda M; Ford I; Robertson M; Böhm M; Borer JS; Steg PG; Tavazzi L; Tendera M; Ferrari R; Swedberg K
Eur Heart J; 2013 Aug; 34(29):2263-70. PubMed ID: 23536611
[TBL] [Abstract][Full Text] [Related]
8. Heart rate in ischemic heart disease. The innovation of ivabradine: more than pure heart rate reduction.
Rosano GM; Vitale C; Volterrani M
Adv Ther; 2010 Apr; 27(4):202-10. PubMed ID: 20495895
[TBL] [Abstract][Full Text] [Related]
9. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).
Tendera M; Talajic M; Robertson M; Tardif JC; Ferrari R; Ford I; Steg PG; Fox K;
Am J Cardiol; 2011 Mar; 107(6):805-11. PubMed ID: 21247517
[TBL] [Abstract][Full Text] [Related]
10. Resting heart rate in cardiovascular disease.
Fox K; Borer JS; Camm AJ; Danchin N; Ferrari R; Lopez Sendon JL; Steg PG; Tardif JC; Tavazzi L; Tendera M;
J Am Coll Cardiol; 2007 Aug; 50(9):823-30. PubMed ID: 17719466
[TBL] [Abstract][Full Text] [Related]
11. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
Canet E; Lerebours G; Vilaine JP
Ann N Y Acad Sci; 2011 Mar; 1222():90-9. PubMed ID: 21434947
[TBL] [Abstract][Full Text] [Related]
12. Elevated heart rate in cardiovascular diseases: a target for treatment?
Palatini P
Prog Cardiovasc Dis; 2009; 52(1):46-60. PubMed ID: 19615493
[TBL] [Abstract][Full Text] [Related]
13. Heart rate control in an unselected consecutive population of outpatients with stable coronary artery disease: Analysis of the CARDIf Study Cohort.
Vitale C; Iellamo F; Volterrani M; Lombardi M; Fini M; Banach M; Rosano GM
Angiology; 2010 Nov; 61(8):763-7. PubMed ID: 20462892
[TBL] [Abstract][Full Text] [Related]
14. Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice.
Di Franco A; Sarullo FM; Salerno Y; Figliozzi S; Parrinello R; Di Pasquale P; Lanza GA
Am J Cardiovasc Drugs; 2014 Apr; 14(2):101-10. PubMed ID: 24327100
[TBL] [Abstract][Full Text] [Related]
15. Heart rate and cardiovascular protection.
Caetano J; Delgado Alves J
Eur J Intern Med; 2015 May; 26(4):217-22. PubMed ID: 25704330
[TBL] [Abstract][Full Text] [Related]
16. Ivabradine: recent and potential applications in clinical practice.
Riccioni G
Expert Opin Pharmacother; 2011 Feb; 12(3):443-50. PubMed ID: 21254949
[TBL] [Abstract][Full Text] [Related]
17. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
[TBL] [Abstract][Full Text] [Related]
18. Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial.
Danchin N
Therapie; 2009; 64(2):111-4. PubMed ID: 19664404
[TBL] [Abstract][Full Text] [Related]
19. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
Perry CM
Am J Cardiovasc Drugs; 2012 Dec; 12(6):415-26. PubMed ID: 23181944
[TBL] [Abstract][Full Text] [Related]
20. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
Fox K; Ford I; Steg PG; Tendera M; Robertson M; Ferrari R;
Eur Heart J; 2009 Oct; 30(19):2337-45. PubMed ID: 19720635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
